Moretto, R.
355  results:
Search for persons X
?
1

Immune-related pan-cancer gene expression signatures of pat..:

D'Angelo A ; Kilili H ; Chapman R...
info:eu-repo/semantics/altIdentifier/pmid/36649303.  , 2023
 
?
2

Encorafenib plus cetuximab with or without binimetinib in p..:

Boccaccino, A ; Borelli, B ; Intini, R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271503/.  , 2022
 
?
3

Treatments after progression to first-line FOLFOXIRI and be..:

Rossini D ; Lonardi S ; Antoniotti C...
info:eu-repo/semantics/altIdentifier/pmid/33024268.  , 2021
 
?
4

The pan-immune-inflammation value is a new prognostic bioma..:

Fuca G ; Guarini V ; Antoniotti C...
info:eu-repo/semantics/altIdentifier/pmid/32424148.  , 2020
 
?
 
?
6

AtezoTRIBE : a randomised phase II study of FOLFOXIRI plus ..:

Antoniotti C ; Borelli B ; Rossini D...
info:eu-repo/semantics/altIdentifier/pmid/32698790.  , 2020
 
?
 
?
8

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma:..:

Dell'Aquila E ; Zeppola T ; Stellato M...
info:eu-repo/semantics/altIdentifier/wos/WOS:000559745000001.  , 2020
 
?
 
?
10

Upfront FOLFOXIRI plus bevacizumab and reintroduction after..:

Cremolini C ; Antoniotti C ; Rossini D...
info:eu-repo/semantics/altIdentifier/pmid/32164906.  , 2020
 
?
11

Efficacy of retreatment with anti-EGFRs in metastatic color..:

Rossini D ; Pagani F ; Pellino A...
info:eu-repo/semantics/altIdentifier/wos/WOS:000475860200428.  , 2019
 
?
12

Clinical and molecular determinants of extrahepatic disease..:

Ongaro E ; Cremolini C ; Rossini D...
info:eu-repo/semantics/altIdentifier/pmid/31231562.  , 2019
 
?
13

Temozolomide and irinotecan (TEMIRI regimen) as salvage tre..:

Morano, F ; Corallo, S ; Niger, M...
info:eu-repo/semantics/altIdentifier/pmid/29860358.  , 2018
 
?
 
?
 
1-15